Share This:
https://ntp.niehs.nih.gov/go/14882

Abstract for TR-502 - Chloral Hydrate (CASRN 302-17-0)

Abstract

Toxicology and Carcinogenesis Studies of Chloral Hydrate (CAS No. 302-17-0) in B6C3F1 Mice (Gavage Studies)

Link to the full study report in PDF. If you have difficulty accessing the document, please send email to the NTP Webmaster [ Send Email ] and identify documents/pages for which access is required.  

 

 

 

Chemical Formula: C2H3Cl3O2

Chloral hydrate is used medically as a sedative or hypnotic and as a rubefacient in topical preparations, and it is often given to children as a sedative during dental and other medical procedures. Chloral hydrate is used as a central nervous system depressant and sedative in veterinary medicine and as a general anesthetic in cattle and horses. It is a byproduct of the chlorination of water and has been detected in plant effluent after the bleaching of softwood pulp. Chloral, the anhydrous form of chloral hydrate, is used as a synthetic intermediate in the production of insecticides and herbicides. Chloral hydrate was nominated for study by the Food and Drug Administration based upon widespread human exposure and its potential hepatotoxicity and the toxicity of related chemicals. One goal of the study was to assess the effect of the animal's age and the duration of dosing on the tumorigenicity of chloral hydrate. Beginning on post-natal day 28, female B6C3F1 mice received chloral hydrate (99.5% pure) in water by gavage for 3, 6, or 12 months, 2 years, or as a single dose;on postnatal day 15, male and female B6C3F1 mice received a single dose by gavage. Tumorigenicity was assessed for 2 years after the initial dose. Genetic toxicology studies were conducted in Salmonella typhimurium, cultured Chinese hamster ovary cells, Drosophila melanogaster, and mouse bone marrow cells.

2-YEAR STUDY

Groups of female mice (regimens A, B, C, and D) and groups of male mice (regimen E) received chloral hydrate in distilled water by gavage; control groups received distilled water only. In regimen A, groups of 48 female mice received 0, 25, 50, or 100 mg chloral hydrate/kg body weight 5 days per week for 105 weeks beginning when they were 28 days old. In regimen B, 24 female mice received 0 mg/kg and three groups of 48 female mice received 100 mg/kg 5 days per week beginning when they were 28 days old. Eight mice from the 0 and 100 mg/kg groups were killed at 3, 6, and 12 months. The remaining mice were held without dosing for the duration of the 2-year study. In regimen C, groups of 48 female mice received a single dose of 0, 10, 25, or 50 mg/kg when they were 28 days old and were held for 105 weeks. In regimens D and E, groups of 48 female and 48 male mice, respectively, received a single dose of 0, 10, 25 or 50 mg/kg when they were 15 days old and were held for 105 weeks. Additional groups of four mice from regimens C, D, and E and mice killed at 3 or 6 months from regimen B (eight mice per group) were designated for hepatic cell proliferation analyses; mice killed at 3 or 6 months in regimen B were also designated for apoptosis analyses.

Survival and Body Weights 
Survival of all dosed mice in all regimens was similar to that of the vehicle control groups. Mean body weights of 100 mg/kg female mice in regimen B dosed for 3 or 6 months were generally greater than those of the vehicle controls during the second year of the study. Mean body weights of 25 mg/kg male mice in regimen E were generally less than those of the controls beginning at week 19; mean body weights of 10 and 50 mg/kg mice were generally less than those of the vehicle controls beginning at week 80.

Pathology Findings
A dose-related and significant increase in the incidence of pars distalis adenoma occurred in regimen A 100 mg/kg females. There was also a time-related increase in the incidence of adenoma in female mice administered 100 mg/kg for up to 24 months in regimen B, and the increase in the incidence of this neoplasm at 24 months was significant. There was a significant increase in the severity of pars distalis hyperplasia in regimen A 100 mg/kg female mice.

GENETIC TOXICOLOGY

Chloral hydrate was mutagenic in vitro and in vivo. It induced mutations in Salmonella typhimurium strain TA100, with and without liver S9 activation; an equivocal response was obtained in S. typhimurium strain TA98 in the absence of S9, and no mutagenicity was detected with strain TA1535 or TA1537, with or without S9. Chloral hydrate was shown to produce chromosomal damage in mammalian cells. It induced significant increases in sister chromatid exchanges and chromosomal aberrations in cultured Chinese hamster ovary cells, with and without S9. Results of sex-linked recessive lethal (SLRL) tests in Drosophila melanogaster were inconclusive. Chloral hydrate, administered by feeding, produced an inconclusive increase in SLRL mutations in the germ cells of male flies. Results of an in vivo mouse bone marrow micronucleus test with chloral hydrate were positive.

CONCLUSIONS

Under the conditions of this two-year gavage study, there was equivocal evidence of carcinogenic activity of chloral hydrate in female B6C3F1 mice treated continuously for two years based on increased incidences of pituitary gland pars distalis adenoma. No increased incidences of neoplasms were seen in female B6C3F1 mice that received a single dose of chloral hydrate at 15 or 28 days of age or in male B6C3F1 mice that received a single dose of chloral hydrate at 15 days of age. No hepatic carcinogenicity was seen under all dosing conditions.

 

 

Synonyms: Trichloracetaldehyde monohydrate; 1,1,1-trichloro-2,2-ethanediol; 2,2,2-trichloro-1,1-ethanediol

Trade names: Aquachloral Supprettes; Noctec; Somnos


Summary of the 2-Year Carcinogenesis Studies of Chloral Hydrate
Regimens A and B
 

Regimen A
(Female Mice)

Regimen Ba
(Female Mice)

Doses in distilled water by gavage Vehicle control, 25, 50, or 100 mg/kg for 2 years Vehicle control or 100 mg/kg for 3, 6, 12, or 24 months; remaining mice held without dosing for the duration of the study
Body weights Dosed groups similar to the vehicle control group Mice dosed for 3 or 6 months greater than the vehicle controls; mice dosed for 12 months similar to vehicle controls
Survival rates 37/48, 39/48, 43/48, 36/48 37/48, 34/48, 31/48, 33/48, 36/48
Nonneoplastic effects None None
Neoplastic effects None None
Equivocal effects Pituitary gland (pars distalis): adenoma (0/45, 2/44, 0/47, 5/41) Pituitary gland (pars distalis): adenoma (0/45, 3/36, 1/36, 1/33, 5/41)
Level of evidence of carcinogenic activity for regimens A and B

 
Equivocal evidence

 a Includes regimen A vehicle control group and regimen A 100 mg/kg group dosed for 2 years.

 

Genetic Toxicology of Chloral Hydrate
Assay Test System Results
Bacterial Mutagenicity Salmonella typhimurium gene mutations: Positive in strain TA100 with and without S9; negative in strains TA1535 and TA1537 with and without S9; equivocal in strain TA98 without S9
Sister chromatid exchanges Cultured Chinese hamster ovary cells in vitro: Positive with and without S9
Chromosomal aberrations Cultured Chinese hamster ovary cells in vitro: Positive with and without S9
Sex-linked recessive lethal mutations Drosophila melanogaster: Inconclusive when administered in feed
Negative when administered as intraperitoneal injection
Micronucleated erythrocytes Mouse bone marrow in vivo: Positive

 

 

Summary of the 2-Year Carcinogenesis Study of Chloral Hydrate - Regimens C, D, and E
 

Regimen C
(Female Mice)

Regimen D
(Female Mice)

Regimen E
(Male Mice)

Doses in distilled water by gavage Single dose of 0, 10, 25, or 50 mg/kg at 28 days of age Single dose of 0, 10, 25, or 50 mg/kg at 15 days of age Single dose of 0, 10, 25, or 50 mg/kg at 15 days of age
Body weights Dosed groups similar to the vehicle control group Dosed groups similar to the vehicle control group Dosed groups generally less than the vehicle control group
Survival rates 42/48, 40/48, 45/48, 40/48 36/48, 41/48, 39/48, 40/48 45/48, 41/48, 46/48, 40/48
Nonneoplastic effects None None None
Neoplastic effects None None None

Report Date: February 2002

Pathology Tables, Survival and Growth Curves from NTP 2-year Studies

Target Organs and Incidences for 2-year Studies


Return to Long Term Abstracts